WASHINGTON (AP) — Federal health officials on Tuesday approved a first-of-a-kind drug that uses the herpes virus to infiltrate and destroy deadly skin cancer tumors.The Food and Drug Administration approved the injectable drug from Amgen Inc. for patients with hard-to-treat melanoma, the deadliest form of skin cancer that is expected to be diagnosed in 74,000 U.S. patients this year. For now, the drug is only approved for melanoma tumors that cannot be removed surgically.
WASHINGTON (AP) -- Scientists for the Food and Drug Administration say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects....
WASHINGTON — Scientists for the Food and Drug Administration say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects.
By Bryce Istvan:Xgeva, part of the Denosumab family, is Amgen’s (AMGN) latest bone related drug. Its current indication is for the treatment of skeletal related events (SREs) caused by bone metastases in all cancers excluding multiple myelomas.
Medivation Inc. (MDVN) and ASTELLAS PHARMA INC.’s (ALPMY) jointly developed drug, Xtandi, is likely to make a dent in the sales of Johnson & Johnson’s (JNJ) drug Zytiga given its more favorable safety profile in treating pre-chemotherapy prostate cancer patients.
Amgen Inc. (AMGN) received a boost recently when the company announced positive results from a pivotal head-to-head phase III study that was conducted with Amgen’s main pipeline candidate, denosumab.
Amgen, Inc. (NASDAQ:AMGN) has said that Blincyto, the company’s new drug for the treatment of a deadly form of leukemia, will cost $178,000 for a standard course of treatment, making it one of the most expensive cancer treatments in the market.